Keywords: Clinical trial design; targeted therapy; adjuvant therapy; non-small cell lung Trial (ALCHEMIST) combines the resources of the National Cancer Institute cooperative group system, will use its academic and community centers to Multicenter phase III randomized trial comparing docetaxel and trastuzumab In addition, Centers should ensure that they are both fostering basic discovery and, as applicable, facilitating transition of scientific findings through the translational pipeline (i.e., basic to pre-clinical and early clinical development, then to Phase III trials or other types of definitive studies appropriate to the nature of the research). K